News >

Luspatercept Data Published in NEJM Highlight Benefit for Beta Thalassemia-Associated Anemia

Jason M. Broderick @jasoncology
Published: Friday, Mar 27, 2020

Diane McDowell, MD, vice president, Hematology Global Medical Affairs, Bristol Myers Squibb

Diane McDowell, MD

Results from the pivotal phase III BELIEVE trial, which supported the FDA approval of luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions, have been published in the New England Journal of Medicine.

The most common grade ≥3 AEs occurring with luspatercept were anemia (3.1% vs 0%), increased liver iron concentration (2.7% vs 0.9%) and hyperuricemia (2.7% vs 0%). Serious AEs occurred in 15.2% versus 5.5% of the luspatercept versus placebo arms, respectively. There was 1 death due to an unconfirmed case of acute myeloid leukemia.
Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020;382(13):1219-1231. doi: 10.1056/NEJMoa1910182.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication